Toxicity information regarding margetuximab is not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects such as infusion-related reactions. Symptomatic and supportive measures are recommended.L27986
The HER2 oncoprotein, the product of the human ERBB2/mouse neu genes, is a member of the HER family of receptor tyrosine kinases that includes the epidermal growth factor receptor (EGFR). Of the various subtypes of breast cancer, HER2-positive breast cancer is characterized by ERBB2 overexpression, a higher grade, a more aggressive phenotype, and a worse prognosis compared to HER2-negative cancer.A225751 The introduction of trastuzumab improved patient outcomes in HER2-positive breast cancer, but notably depended substantially on polymorphisms in the Fc?RIIIA/CD16A receptor, whereby low affinity 158F CD16A variants are associated with shorter progression-free survival and worse patient outcomes.A225756
Margetuximab (formerly MGAH22) is an Fc-engineered human/mouse chimeric anti-HER2 IgG1? monoclonal antibody derived from the same mouse 4D5 clone that trastuzumab is derived from and is produced in Chinese Hamster Ovary (CHO) culture.A225751, A225756, A225766, A191829, L27986 Margetuximab binds to the same epitope on the HER2 extracellular domain and induces the same effects as trastuzumab. However, due to its modified Fc region, margetuximab binds with higher affinity to both CD16A variants and exhibits weaker binding to the inhibitory CD32B Fc receptor, resulting in more efficient antibody-dependent cell-mediated cytotoxicity (ADCC) and increased efficacy compared to trastuzumab.A225751, A225756, A225766, A191829, L27986
Margextuximab was granted FDA approval on December 16, 2020, and is currently marketed under the trademark MARGENZA™ by MacroGenics, Inc.L27986
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Margetuximab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Margetuximab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Margetuximab. |
| Estrone | Estrone may increase the thrombogenic activities of Margetuximab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Margetuximab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Margetuximab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Margetuximab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Margetuximab. |
| Estriol | Estriol may increase the thrombogenic activities of Margetuximab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Margetuximab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Margetuximab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Margetuximab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Margetuximab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Margetuximab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Margetuximab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Margetuximab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Margetuximab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Margetuximab. |
| Equol | Equol may increase the thrombogenic activities of Margetuximab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Margetuximab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Margetuximab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Margetuximab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Margetuximab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Margetuximab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Margetuximab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Margetuximab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Margetuximab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Margetuximab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Margetuximab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Margetuximab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Margetuximab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Margetuximab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Margetuximab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Margetuximab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Margetuximab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Margetuximab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Margetuximab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Margetuximab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Margetuximab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Margetuximab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Margetuximab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Margetuximab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Margetuximab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Margetuximab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Margetuximab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Margetuximab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Margetuximab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Margetuximab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Margetuximab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Margetuximab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Margetuximab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Margetuximab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Margetuximab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Margetuximab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Margetuximab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Margetuximab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Margetuximab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Margetuximab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Margetuximab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Margetuximab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Margetuximab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Margetuximab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Margetuximab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Margetuximab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Margetuximab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Margetuximab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Margetuximab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Margetuximab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Margetuximab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Margetuximab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Margetuximab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Margetuximab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Margetuximab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Margetuximab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Margetuximab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Margetuximab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Margetuximab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Margetuximab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Margetuximab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Margetuximab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Margetuximab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Margetuximab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Margetuximab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Margetuximab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Margetuximab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Margetuximab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Margetuximab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Margetuximab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Margetuximab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Margetuximab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Margetuximab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Margetuximab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Margetuximab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Margetuximab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Margetuximab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Margetuximab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Margetuximab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Margetuximab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Margetuximab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Margetuximab. |